featured
Outcomes of Patients With Large B-Cell Lymphomas, Including Primary Mediastinal Large B-Cell Lymphoma, Receiving Axicabtagene Ciloleucel
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Leukemia
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study
Leukemia 2024 Mar 08;[EPub Ahead of Print], A Chiappella, B Casadei, P Chiusolo, A Di Rocco, S Ljevar, M Magni, P Angelillo, AM Barbui, I Cutini, A Dodero, F Bonifazi, MC Tisi, S Bramanti, M Musso, M Farina, M Martino, M Novo, G Grillo, F Patriarca, G Zacchi, M Krampera, M Pennisi, E Galli, M Martelli, AJM Ferreri, S Ferrari, R Saccardi, A Bermema, A Guidetti, R Miceli, PL Zinzani, P CorradiniFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.